Saturday, 31 October 2026European Markets

ELECTROMAGNET GEO Stock Bearish By 17% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ELECTROMAGNET GEO (Oslo Børs Benchmark Index_GI: EMGS.OL) fell by a staggering 17.14% in 5 sessions from kr3.15 to kr2.61 at 14:22 EST on Thursday, after four successive sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.55% to kr1,244.89, following the last session's downward trend.

About ELECTROMAGNET GEO

Electromagnetic Geoservices ASA, together with its subsidiaries, provides electromagnetic (EM) surveying services to the offshore oil and gas exploration industry. It is involved in the planning, acquisition, processing, modelling, interpretation, and integration of EM data. The company uses its patented EM survey method to find hydrocarbons in offshore reservoirs. It engages in the provision of controlled-source EM surveying and magneto telluric surveying; imaging and interpretation; rental of software and cluster; and training services. The company has operations in Europe, the Middle East, Africa, Norway, North and South America, Asia, and the Pacific Ocean. Electromagnetic Geoservices ASA was incorporated in 2002 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ELECTROMAGNET GEO has a trailing twelve months EPS of kr0.9.

PE Ratio

ELECTROMAGNET GEO has a trailing twelve months price to earnings ratio of 2.9. Meaning, the purchaser of the share is investing kr2.9 for every norwegian krone of annual earnings.

More news about ELECTROMAGNET GEO (EMGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com